These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29153604)

  • 1. Characterization of isolated tau-reactive antibodies from the IVIG product, plasma of patients with Alzheimer's disease and cognitively normal individuals.
    Krestova M; Hromadkova L; Bilkova Z; Bartos A; Ricny J
    J Neuroimmunol; 2017 Dec; 313():16-24. PubMed ID: 29153604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of natural antibodies against tau protein in an intravenous immunoglobulin product.
    Hromadkova L; Kolarova M; Jankovicova B; Bartos A; Ricny J; Bilkova Z; Ripova D
    J Neuroimmunol; 2015 Dec; 289():121-9. PubMed ID: 26616881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELISA measurement of specific antibodies to phosphorylated tau in intravenous immunoglobulin products.
    Loeffler DA; Klaver AC; Coffey MP
    Int Immunopharmacol; 2015 Oct; 28(2):1108-12. PubMed ID: 26330100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein.
    Smith LM; Coffey MP; Klaver AC; Loeffler DA
    Int Immunopharmacol; 2013 Aug; 16(4):424-8. PubMed ID: 23669333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease.
    Bartos A; Fialová L; Švarcová J
    J Alzheimers Dis; 2018; 64(3):751-760. PubMed ID: 29966192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific binding of intravenous immunoglobulin products to tau peptide fragments.
    Smith LM; Coffey MP; Loeffler DA
    Int Immunopharmacol; 2014 Aug; 21(2):279-82. PubMed ID: 24859060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in concentrations of tau-reactive antibodies are dependent on sex in Alzheimer's disease patients.
    Krestova M; Ricny J; Bartos A
    J Neuroimmunol; 2018 Sep; 322():1-8. PubMed ID: 29789140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of antibody fragment selective for human Alzheimer's disease brain-derived tau variants.
    Venkataraman L; He P; Schulz P; Sierks MR
    Neurobiol Aging; 2020 Oct; 94():7-14. PubMed ID: 32497877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects.
    Rosenmann H; Meiner Z; Geylis V; Abramsky O; Steinitz M
    Neurosci Lett; 2006 Dec; 410(2):90-3. PubMed ID: 17095156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of antibody fragments selective for toxic oligomeric tau.
    Tian H; Davidowitz E; Lopez P; He P; Schulz P; Moe J; Sierks MR
    Neurobiol Aging; 2015 Mar; 36(3):1342-55. PubMed ID: 25616912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tau domain-specific antibodies and intravenous immunoglobulin on tau aggregation and aggregate degradation.
    Esteves-Villanueva JO; Trzeciakiewicz H; Loeffler DA; Martić S
    Biochemistry; 2015 Jan; 54(2):293-302. PubMed ID: 25545358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer's Disease.
    Hromadkova L; Ovsepian SV
    J Immunol Res; 2019; 2019():7406810. PubMed ID: 31687413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.
    Counts SE; Lahiri DK
    Curr Alzheimer Res; 2014; 11(7):623-5. PubMed ID: 25156573
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.
    Klaver AC; Coffey MP; Smith LM; Loeffler DA
    Immunol Lett; 2013; 154(1-2):7-11. PubMed ID: 23928186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
    Strang KH; Goodwin MS; Riffe C; Moore BD; Chakrabarty P; Levites Y; Golde TE; Giasson BI
    Acta Neuropathol Commun; 2017 Jul; 5(1):58. PubMed ID: 28760159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
    Solomon B
    Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Assay and Anti-Inflammatory Function Evaluation of Therapeutic Potential of Different Intravenous Immunoglobulins for Alzheimer's Disease.
    Fei Z; Pei R; Pan B; Ye S; Zhang R; Ma L; Wang Z; Li C; Du X; Cao H
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.